PTO/SR/21 (01-03)

		U.S. Paten	Approved for use through 04/30/2003. OMB 0651-003 it and Trademark Office; U.S. DEPARTMENT OF COMMERC		
Hands Under the Paperwork Reduction Act of 1995.	no persons	are required to respond to a collection Application Number	on of information unless it displays a valid OMB control number 10/626,681		
TRANSMITTAL		Filing Date	July 24, 2003		
FORM		First Named Inventor	Alanine		
(to be used for all correspondence after initial fi	lina)	Art Unit			
1.0 20 200 to an oan oap on an oan oan oan oan oan oan oan oan o	3/	Examiner Name			
		Attorney Docket Number			
Total Number of Pages in This Submission		Altorney Docket Number	21237		
	ENCL	OSURES (Check all that	t apply)		
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	F F F F F F F F F F F F F F F F F F F	Prawing(s) icensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Perminal Disclaimer Request for Refund CD, Number of CD(s) m 1449, Search Report with Refe	Other Enclosure(s) (please identify below):		
SIGNAT	URE O	F APPLICANT, ATTORNI	EY, OR AGENT		
Firm or Individual Signature Date January 14, 2004	7/	Cu			
	DTICIO	ATE OF TRANSMISSION	UMAII INC		
I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date January 14, 2004					
Typed or printed Dennis P. Tramalo	ni				
Signature		1 ,	Date January 14, 2004		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s): Alanine, et al.

Group:

Serial No. 10/626,681, filed July 24, 2003

Examiner:

For: **BENZODIOXOLE DERIVATIVES** 

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 Date: January 14, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A2, A3, B15-B20 and C22 listed on Form PTO-1449 are enclosed.

Enclosed is a Search Report, dated November 25, 2003, which was issued by the European Searching Authority in the corresponding PCT application. The Search Report lists Documents A2, A3, B15-B21 and C18, C20, C21, and C22. Document B16, which is not written in the English language, corresponds to Document A3, U.S. Patent No. 6,432,984, which is not being submitted because it is a U.S. Patent. Documents A2 and A3 are not being submitted because they are U.S. Patents. Documents C18, C20, and C21 are not enclosed since they have previously been submitted in Applicant's Information Disclosure Statement mailed August 27, 2003.

Serial No. 10/626,681

Filed: July 24, 2003

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Supplemental Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application and/or because each item of information contained in the Supplemental Information Disclosure Statement was cited in a communication for the first time from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Dennis P. Tramaloni

(Reg. No. 28,542) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-4475

Telefax: (973) 235-2363

137211

	Substitute for form 1449A/PTO			for form 1449A/PTO	Complete if Known			
1018	1	NFORMA	ATION	N DISCLOSURE	Application Number	10/626,681		
/01°	15/8	STATEMI	ENT E	SY APPLICANT	Filing Date	July 24, 2003		
	స\				First Name Inventor	Alanine		
IAN 1 B	JAN 1 6 2004 & (Use several sh	veral sheets if necessary)		Group Art Unit				
3 JAN 1 2				Examiner Name				
THE STATE OF THE S	Sheet	1	of	1	Attorney Docket Number	21237		
TRADE	MAR	<u> </u>	1	U.S. PA	TENT DOCUMENTS	•		
			Ī	J.S. Patent Document				

Sheet	l	of 1	A	Attorney Docket Number 21	237		
Mili				NT DOCUMENTS			
Examiner Initials'	Cite No.'	U.S. Patent Document  Kind Code²  Number (if known)		Name of Patentee or Applicant of Cited Document		Date of Publication of Cited document MM-DD-YYYY	
	A2	2002/019383		Achard, et al.		02-14-2002	
	A3	2001/034344		Mittendorf, et al.		10-25-2001	
	A4	6,432,984		Barth, et al.		08-13-2002	
	<u> </u>	FO	REIGN PA	TENT DOCUMENTS			
Examiner Initials'	Cite No.'	Foreign Patent Docum Office <sup>3</sup> Number <sup>4</sup>	Kind Code <sup>5</sup>	Name of Patentee or Applicant of Cited Document	c	e of Publication of Cited Document IM-DD-YYYY	Τ <sup>*</sup>
	B15	WO 92 18490	1 (11 1111 1111)	Hoffmann-La Roche	10-	29-1992	
	B16	FR 2 789 078		Sanofi SA	08-	04-2000	V
	B17	WO 01 28557		University of Connecticut	04-	26-2001	
	B18	WO 01 29007		University of Connecticut	04-	26-2001	
	B19	WO 02 36590		Amrad Operations Pty Ltd.	05-	10-2002	
	B20	WO 02 42248		Novartis AG	05-	30-2002	
Examiner Signature		Date Considered					

Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Unique citation designation number. \*See attached Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation or abstract is attached.

	Substitute for form 1449A/PTO	Complete if Known		
1018	INFORMATION DISCLOSURE	Application Number	10/626,681	
/ 5	STATEMENT BY APPLICANT	Filing Date	July 24, 2003	
JAN 1 6 2004 8		First Name Inventor	Alanine	
JAN 1 PE	(Use several sheets if necessary)	Group Art Unit		
		Examiner Name		
TRADENTSHeet	2 of 2	Attorney Docket Number	21237	

NON PATENT LITERATURE DOCUMENTS

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials'	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C22	PATENT ABSTRACTS OF JAPAN, Vol. 015, No. 001, (1991)	
	022	& JP 02 0255673 A., FUJI PHOTO FILM CO LTD, (1990)	
		(1990)	
	_		
	_		
,			_
	<del></del>		<b> </b>
			-
			<u> </u>
			<u> </u>
			<u> </u>
Examiner Signature		DATE CONSIDERED	
Digitature		CONTRIBUTION	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

137202

, . .